Abstract
Innovations and discoveries in cancer therapeutics have improved survival rates in patients with various types of malignancies. At the same time, physicians are identifying an increased number of patients with treatment-related cardiotoxicity. It is imperative that physicians recognize early treatment-related adverse effects to determine the safest therapeutic options for patients with cancer. This manuscript evaluates the role of cardiovascular imaging and biomarkers in identifying cardiotoxicity trigged by various chemotherapeutic agents and summarizes expert consensus statements regarding cardiotoxicity monitoring.
PMID: 31988686 [PubMed - in process]
16:00
Photo
Not included, change data exporting settings to download.
256×256, 6.0 KB
16:00
In reply to this message
pubmed: ctoall&ca or conall
Heart Failure in Relation to Tumor-Targeted Therapies and Immunotherapies.
Related Articles
Heart Failure in Relation to Tumor-Targeted Therapies and Immunotherapies.
Methodist Debakey Cardiovasc J. 2019 Oct-Dec;15(4):250-257
Authors: Agunbiade TA, Zaghlol RY, Barac A
No comments:
Post a Comment
اكتب تعليق حول الموضوع